HomeCompareVMCPX vs JNJ

VMCPX vs JNJ: Dividend Comparison 2026

VMCPX yields 1.16% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VMCPX wins by $1.3K in total portfolio value
10 years
VMCPX
VMCPX
● Live price
1.16%
Share price
$379.15
Annual div
$4.42
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.3K
Annual income
$125.62
Full VMCPX calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — VMCPX vs JNJ

📍 VMCPX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVMCPXJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VMCPX + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VMCPX pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VMCPX
Annual income on $10K today (after 15% tax)
$99.01/yr
After 10yr DRIP, annual income (after tax)
$106.78/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, JNJ beats the other by $596.84/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VMCPX + JNJ for your $10,000?

VMCPX: 50%JNJ: 50%
100% JNJ50/50100% VMCPX
Portfolio after 10yr
$20.7K
Annual income
$476.70/yr
Blended yield
2.30%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

VMCPX
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VMCPX buys
0
JNJ buys
0
No recent congressional trades found for VMCPX or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVMCPXJNJ
Forward yield1.16%3.36%
Annual dividend / share$4.42$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$21.3K$20.0K
Annual income after 10y$125.62$827.78
Total dividends collected$1.2K$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: VMCPX vs JNJ ($10,000, DRIP)

YearVMCPX PortfolioVMCPX Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$10,816$116.48$10,676$355.77+$140.00VMCPX
2$11,691$117.75$11,407$389.39+$284.00VMCPX
3$12,629$118.94$12,198$426.53+$431.00VMCPX
4$13,633$120.08$13,056$467.62+$577.00VMCPX
5$14,708$121.14$13,987$513.12+$721.00VMCPX
6$15,860$122.15$14,998$563.56+$862.00VMCPX
7$17,093$123.10$16,098$619.52+$995.00VMCPX
8$18,414$123.99$17,295$681.69+$1.1KVMCPX
9$19,828$124.83$18,599$750.82+$1.2KVMCPX
10$21,341$125.62$20,022$827.78+$1.3KVMCPX

VMCPX vs JNJ: Complete Analysis 2026

VMCPXStock

This low-cost index fund provides broad mid-capitalization U.S. equity exposure. The fund seeks to track an index of medium-sized companies, whose stocks tend to be more volatile than those of larger companies. This potential volatility is one of the fund’s key risks. Investors looking to add a passively managed, mid-cap stock allocation to an already diversified portfolio may wish to consider this fund.

Full VMCPX Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this VMCPX vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VMCPX vs SCHDVMCPX vs JEPIVMCPX vs OVMCPX vs KOVMCPX vs MAINVMCPX vs ABBVVMCPX vs MRKVMCPX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.